Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.

Am J Hematol

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

Published: December 2016

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are myeloproliferative neoplasms characterized by recurrent somatic mutations in JAK2, CALR, and MPL. This short review addresses (1) the spectrum of mutations seen in PV, ET, and PMF, (2) the emerging genotype-phenotype correlations, (3) the current role of molecular testing in disease classification and management, and (4) several important considerations for selecting an appropriate molecular test. In our view, sequential testing algorithms and simultaneous assessment of multiple mutations by next-generation sequencing are both valid approaches to testing. Am. J. Hematol. 91:1277-1280, 2016. © 2016 Wiley Periodicals, Inc.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24578DOI Listing

Publication Analysis

Top Keywords

molecular testing
8
myeloproliferative neoplasms
8
testing jak2
4
jak2 mpl
4
mpl calr
4
calr myeloproliferative
4
neoplasms polycythemia
4
polycythemia vera
4
vera essential
4
essential thrombocythemia
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!